Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $232.2 million.

  • Integra Lifesciences Holdings' Cash & Equivalents rose 789.96% to $232.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $232.2 million, marking a year-over-year increase of 789.96%. This contributed to the annual value of $246.4 million for FY2024, which is 1085.45% down from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Cash & Equivalents stood at $232.2 million, which was up 789.96% from $217.9 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' Cash & Equivalents' 5-year high stood at $591.9 million during Q1 2024, with a 5-year trough of $215.2 million in Q3 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $309.2 million (2023), whereas its average is $354.6 million.
  • In the last 5 years, Integra Lifesciences Holdings' Cash & Equivalents surged by 9257.3% in 2024 and then crashed by 5960.44% in 2025.
  • Integra Lifesciences Holdings' Cash & Equivalents (Quarter) stood at $513.4 million in 2021, then decreased by 11.06% to $456.7 million in 2022, then plummeted by 39.47% to $276.4 million in 2023, then fell by 10.85% to $246.4 million in 2024, then dropped by 5.76% to $232.2 million in 2025.
  • Its last three reported values are $232.2 million in Q3 2025, $217.9 million for Q2 2025, and $239.1 million during Q1 2025.